首页 > 市场调查报告书 > 医疗设备

药物递输设备

市场调查报告书

商品编码

1439251

全球自动注射器市场：洞察、竞争格局、市场预测：2030 年

Autoinjectors - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日期: 按订单生产 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

简介目录图表

2023年全球自动注射器市场规模为21.7亿美元。预计到 2030 年，该市场将达到 66.9 亿美元，2024 年至 2030 年的预测期间复合年增长率为 20.65%。对自动注射器的需求是由需要立即紧急施用介入药物的适应症数量推动的，例如过敏反应和多发性硬化症、自我给药的能力以及提供传统注射器的安全替代品的能力。预计增长因为这些治疗有有利的报销制度。

由于对治疗药物的紧急管理的需求不断增加，预计自动注射器市场在预测期内将出现显着增长。根据多发性硬化症国际联合会《MS Atlas of MS》第 3 版提供的数据，到 2020 年，全球多发性硬化症 (MS) 患者人数预计将增加至 280 万人。事实确实如此。这项估计比 2013 年的数据增加了 30%。 2020 年全球盛行率为每 10 万人 35.9 例。多发性硬化症 (MS) 是一种使人衰弱的疾病，通常发生在生命的旺盛时期，对患者的生活品质有重大影响。儘管目前尚无治疗多发性硬化症的特效药物，但市面上有许多治疗方法，例如 AVONEX Pens，可以帮助控制与多发性硬化症相关的临床恶化。

过敏反应是另一种发展迅速且可能致命的疾病。过敏反应是一种严重的全身性超敏反应，通常发展迅速且可能致命。过敏反应可以定义为一种快速进展的、全身性、多系统的过敏反应。根据美国气喘和过敏基金会 2023 年的数据，过敏是美国慢性病的第六大常见原因。此外，美国每年有超过 5000 万人患有各种类型的过敏症。这些过敏会引起过敏性休克，需要立即註射肾上腺素。

此外，自註射器在帮助患有针头恐惧症的患者方面还有其他好处，包括近乎无痛的给药、成本效益、降低针刺伤害的风险以及提高患者的依从性。

然而，市场上传统针头和注射器等替代产品的存在可能会限制预测期内自动注射器市场的成长。

本报告调查了全球自动注射器市场，并提供了市场概述，以及按产品类型、类型、便携性、应用、最终用户、地区和进入市场的公司概况等划分的趋势。

Autoinjectors Market By Product Type (Disposable and Reusable), Type (Prefilled and Fillable), Portability (Handheld and Wearable), Indication (Rheumatoid Arthritis, Diabetes, Anaphylaxis, Multiple Sclerosis, and Others), End-User (Hospitals, Clinics, and Homecare Settings), and Geography is expected to grow at a steady CAGR forecast till 2030 owing to rising technological advancement and increasing prevalence of chronic diseases.

The global autoinjectors market was valued at USD 2.17 billion in 2023, growing at a CAGR of 20.65% during the forecast period from 2024 to 2030 to reach USD 6.69 billion by 2030. The demand for autoinjectors is witnessing growth due to the number of indications requiring immediate and emergency administration of interventional drugs such as anaphylaxis and multiple sclerosis, allows for self-administration of drugs, offers a safe alternative to conventional syringes, and the favorable reimbursement programs for these procedures.

Autoinjectors Market Dynamics:

The autoinjectors market is estimated to register significant growth in the forecast period on account of the growing need for emergency administration of therapeutic drugs. As per the data provided by the Multiple Sclerosis International Federation, Atlas of MS, 3rd Edition, in 2020, the estimates of the number of people living with MS worldwide increased to 2.8 million in 2020. The estimates presented a 30% increase from 2013 data. The 2020 global prevalence is 35.9 per 100,000 people. Multiple sclerosis (MS) is a debilitating indication that usually presents at a highly productive stage of life and can massively impact the quality of life of patients. Even though there is no specific cure for the indication at present for the treatment of MS, many therapies such as AVONEX Pens are available in the market that helps in controlling clinical exacerbations associated with MS.

Anaphylaxis is another indication that sets in rapidly and may even lead to death. It is a serious systemic hypersensitivity reaction that is usually rapid in onset and may cause death. It can be defined as a rapidly evolving, generalized, multi-system, allergic reaction. According to the data provided by the Asthma and Allergy Foundation of America 2023, allergies are the sixth most common cause of chronic illnesses in the US. It further mentioned that more than 50 million people in the US suffer from different types of allergies in the country each year. As these allergies can manifest into anaphylactic shocks, they require immediate administration of epinephrine injections, which are also being sold in prefilled autoinjector form by certain companies.

Furthermore, the added advantages associated with the autoinjectors such as virtually painless administration of medication, cost-effectiveness, reduced risk of needle stick accidents, and increased patient compliance in terms of helping people with needle phobia.

However, the availability of alternative products such as conventional needles and syringes in the market may restrain the growth of the autoinjectors market during the forecast period.

Autoinjectors Market Segment Analysis:

Autoinjectors Market by Product Type (Disposable and Reusable), Type (Prefilled and Fillable), Portability (Handheld and Wearable), Indication (Rheumatoid Arthritis, Diabetes, Anaphylaxis, Multiple Sclerosis, and Others), End-User (Hospitals, Clinics, and Homecare Settings), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the product segment of the autoinjectors market, the disposable autoinjectors category is estimated to amass a larger market share in the historic period. This can be attributed to their preferred use among end-users due to the presence of a built-in glass syringe which eliminated the need for the manual insertion of the glass syringe. These types of syringes prove to be useful for patients with visual impairments and reduced limb mobility.

Also, owing to the technological advancements in product development, there has been an increase in the number of reusable autoinjectors in the market. These autoinjectors allow for the replacement of the drug cartridges after the expiration of the shelf-life. Moreover, to keep up with the demand for smart technologies in the market, companies have also started offering smart reusable autoinjectors as well such as SmartPilot and Aria Smart Autoinjector, thereby projecting a fast growth period for this product category in the forecast period.

North America is expected to dominate the Overall Autoinjectors Market:

Among all the regions, North America is expected to account for the largest share of the autoinjectors market. This can be attributed to the increasing cases of indications such as rheumatoid arthritis, migraine, MS, and anaphylaxis among others, the presence of a highly aware patient pool, as well as better healthcare access in the region.

As per the data provided by the Migraine Research Foundation (2023), approximately 39 million people including both children and adult populations suffer from migraine in the country. It further stated that more than 4 million people experience chronic migraine episodes daily in the US. Migraine is an extremely debilitating neurological illness that leaves over 90% of sufferers in a compromised state unable to work or function normally during their migraine.

Furthermore, according to the National Multiple Sclerosis Society, United States, in 2022, it has been estimated that about one million people are currently living in the country with MS, which is twice the number of previous estimates. These indications among others can drastically affect the quality of life of patients and more so often require urgent administration of the therapeutic drug in events of sporadic onset of an episode.

Moreover, the US Food and Drug Administration (FDA) is a highly active regulatory body that focuses not only on the careful regulation of the approval processes of medical devices and pharmaceutical products but also engages extensively in educating patients and caregivers regarding new treatment methods, products, and even adversities related to them. This has resulted in the presence of a highly aware patient population in the country.

Additionally, the large presence of key market players in the country as well as the launch of new products in the country also provide favorable conditions for the growth of the Autoinjectors market in the region.

In August 2020, the US FDA approved Kesimpta® (as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It is the first B-cell therapy that can be self-administered by patients via the Sensoready autoinjector pen.

Therefore, owing to the above-mentioned factors, the market for autoinjectors in the United States and North America is predicted to witness significant growth in the forecast period.

Autoinjectors Market Key Players:

Some of the key market players operating in the autoinjectors market include BD, Ysmoed AG, Sonceboz, Phillips-Medisize, Nemera, Novartis, Teva Pharmaceuticals, Amgen, GSK, Mylan Inc, Elcam Medical, Union Medico Injection Safety ApS, SHL Medical AG, Haselmeier, Owen Mumford Ltd, and others.

Recent Developmental Activities in Autoinjectors Market:

In May 2022, Phillips-Medisize, a Molex Company launched their Aria Smart Autoinjector Platform. This includes a small smart injectable device that features a reusable electronic drive unit and single-use disposable cassettes.

In January 2020, Teva Pharmaceuticals received product approval from the US Food and Drug Administration for the autoinjector for the delivery of remanezumab, an anti-calcitonin gene-related peptide (anti-CGRP) approved for the prevention of migraine in adults.

In October 2019, BD launched the BD Intevi 1mL two-step disposable autoinjector. This device combines an autoinjector and pre-fillable syringe in one integrated system.

Key Takeaways from the Autoinjectors Market Report Study

Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global autoinjectors market.

Various opportunities available for the other competitor in the autoinjectors market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current autoinjectors market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for autoinjectors market growth in the coming future?

Target Audience who can be benefited from this Autoinjectors Market Report Study

Autoinjectors products providers

Research organizations and consulting companies

Autoinjectors-related organization, association, forum, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in autoinjectors

Various End-Users who want to know more about the autoinjectors market and the latest technological developments in the autoinjectors market.

Frequently Asked Questions for Autoinjectors Market:

1. What are Autoinjectors?

An autoinjector device (AID) is a medical device that is employed in the administration of drugs majorly in emergencies. They help in the administration of drugs commonly via subcutaneous or intramuscular routes.

2. What is the market for global autoinjectors?

The global autoinjectors market was valued at USD 2.17 billion in 2023, growing at a CAGR of 20.65% during the forecast period from 2024 to 2030 to reach USD 6.69 billion by 2030.

3. What are the drivers for the global autoinjectors market?

The major factors driving the demand for autoinjectors in the market are the rising prevalence of indications that require emergency administration of drugs such as multiple sclerosis and anaphylaxis, the flexibility of self-administration of drugs, and the advantages over conventional syringes, among other factors.

4. What are the key players operating in the global autoinjectors market?

5. What region has the highest share in the autoinjectors market?

North America is expected to account for the highest revenue share in the autoinjectors market during the forecast period. Factors such as the presence of a highly-aware patient population in terms of device technology, better healthcare access along with the presence of a large patient population in the region are expected to be major influencing factors in the North American autoinjectors market.

1. Autoinjectors Market Report Introduction

2. Autoinjectors Market Executive Summary

2.1. Scope of the Study
2.2. Market at Glance
2.3. Competitive Assessment

3. Regulatory Analysis

3.1. The United States
3.2. Europe
3.3. Japan
3.4. China

4. Autoinjectors Market Key Factors Analysis

4.1. Autoinjectors Market Drivers
- 4.1.1. Rising Prevalence of Indications Requiring Emergency Medication Administration
- 4.1.2. Ease of Self-Administration of Drugs
- 4.1.3. Benefits Over Syringes
- 4.1.4. Technological Advancements Leading to Innovative Product Development
4.2. Autoinjectors Market Restraints and Challenges
- 4.2.1. Availability of Alternative Products
- 4.2.2. Less Awareness Regarding Autoinjectors in Developing Economies
4.3. Autoinjectors Market Opportunities
- 4.3.1. Targeting Emerging Markets for Product Launches
- 4.3.2. Product Improvement in Terms of Safety

5. Autoinjectors Market Porter's Five Forces Analysis

5.1. Bargaining Power of Suppliers
5.2. Bargaining Power of Consumers
5.3. Threat of New Entrants
5.4. Threat of Substitutes
5.5. Competitive Rivalry

6. Autoinjectors Market Layout

6.1. By Product Type
- 6.1.1. Disposable
- 6.1.2. Reusable
6.2. By Type
- 6.2.1. Prefilled
- 6.2.2. Fillable
6.3. By Portability
- 6.3.1. Handheld
- 6.3.2. Wearable
6.4. By Application
- 6.4.1. Rheumatoid Arthritis
- 6.4.2. Diabetes
- 6.4.3. Anaphylaxis
- 6.4.4. Multiple Sclerosis
- 6.4.5. Others
6.5. By End-User
- 6.5.1. Hospitals
- 6.5.2. Clinics
- 6.5.3. Others
6.6. By Geography
- 6.6.1. North America Autoinjectors Market Size in USD million (2021-2030)
  - 6.6.1.1. United States Autoinjectors Market Size in USD million (2021-2030)
  - 6.6.1.2. Canada Autoinjectors Market Size in USD million (2021-2030)
  - 6.6.1.3. Mexico Autoinjectors Market Size in USD million (2021-2030)
- 6.6.2. Europe Autoinjectors Market Size in USD million (2021-2030)
  - 6.6.2.1. France Autoinjectors Market Size in USD million (2021-2030)
  - 6.6.2.2. Germany Autoinjectors Market Size in USD million (2021-2030)
  - 6.6.2.3. United Kingdom Autoinjectors Market Size in USD million (2021-2030)
  - 6.6.2.4. Italy Autoinjectors Market Size in USD million (2021-2030)
  - 6.6.2.5. Spain Autoinjectors Market Size in USD million (2021-2030)
  - 6.6.2.6. Rest of Europe Autoinjectors Market Size in USD million (2021-2030)
- 6.6.3. Asia-Pacific Autoinjectors Market Size in USD million (2021-2030)
  - 6.6.3.1. China Autoinjectors Market Size in USD million (2021-2030)
  - 6.6.3.2. Japan Autoinjectors Market Size in USD million (2021-2030)
  - 6.6.3.3. India Autoinjectors Market Size in USD million (2021-2030)
  - 6.6.3.4. Australia Autoinjectors Market Size in USD million (2021-2030)
  - 6.6.3.5. South Korea Autoinjectors Market Size in USD million (2021-2030)
  - 6.6.3.6. Rest of Asia-Pacific Autoinjectors Market Size in USD million (2021-2030)
- 6.6.4. Rest of the World (RoW) Autoinjectors Market Size in USD million (2021-2030)
  - 6.6.4.1. Middle East Autoinjectors Market Size in USD million (2021-2030)
  - 6.6.4.2. Africa Autoinjectors Market Size in USD million (2021-2030)
  - 6.6.4.3. South America Autoinjectors Market Size in USD million (2021-2030)

7. Autoinjectors Market Company and Product Profiles

7.1. BD
- 7.1.1. Company Overview
- 7.1.2. Company Snapshot
- 7.1.3. Financial Overview
- 7.1.4. Product Listing
- 7.1.5. Entropy
7.2. Ysomed AG
- 7.2.1. Company Overview
- 7.2.2. Company Snapshot
- 7.2.3. Financial Overview
- 7.2.4. Product Listing
- 7.2.5. Entropy
7.3. Sonceboz
- 7.3.1. Company Overview
- 7.3.2. Company Snapshot
- 7.3.3. Financial Overview
- 7.3.4. Product Listing
- 7.3.5. Entropy
7.4. Phillips-Medisize
- 7.4.1. Company Overview
- 7.4.2. Company Snapshot
- 7.4.3. Financial Overview
- 7.4.4. Product Listing
- 7.4.5. Entropy
7.5. Nemera
- 7.5.1. Company Overview
- 7.5.2. Company Snapshot
- 7.5.3. Financial Overview
- 7.5.4. Product Listing
- 7.5.5. Entropy
7.6. Haselmeier
- 7.6.1. Company Overview
- 7.6.2. Company Snapshot
- 7.6.3. Financial Overview
- 7.6.4. Product Listing
- 7.6.5. Entropy
7.7. Teva Pharmaceuticals
- 7.7.1. Company Overview
- 7.7.2. Company Snapshot
- 7.7.3. Financial Overview
- 7.7.4. Product Listing
- 7.7.5. Entropy
7.8. Amgen
- 7.8.1. Company Overview
- 7.8.2. Company Snapshot
- 7.8.3. Financial Overview
- 7.8.4. Product Listing
- 7.8.5. Entropy
7.9. SHL Medical AG
- 7.9.1. Company Overview
- 7.9.2. Company Snapshot
- 7.9.3. Financial Overview
- 7.9.4. Product Listing
- 7.9.5. Entropy
7.10. Union Medico Injection Safety ApS
- 7.10.1. Company Overview
- 7.10.2. Company Snapshot
- 7.10.3. Financial Overview
- 7.10.4. Product Listing
- 7.10.5. Entropy
7.11. Elcam Medical
- 7.11.1. Company Overview
- 7.11.2. Company Snapshot
- 7.11.3. Financial Overview
- 7.11.4. Product Listing
- 7.11.5. Entropy
7.12. Mylan Inc
- 7.12.1. Company Overview
- 7.12.2. Company Snapshot
- 7.12.3. Financial Overview
- 7.12.4. Product Listing
- 7.12.5. Entropy
7.13. NOVARTIS
- 7.13.1. Company Overview
- 7.13.2. Company Snapshot
- 7.13.3. Financial Overview
- 7.13.4. Product Listing
- 7.13.5. Entropy
7.14. Owen Mumford Ltd.
- 7.14.1. Company Overview
- 7.14.2. Company Snapshot
- 7.14.3. Financial Overview
- 7.14.4. Product Listing
- 7.14.5. Entropy
7.15. GSK
- 7.15.1. Company Overview
- 7.15.2. Company Snapshot
- 7.15.3. Financial Overview
- 7.15.4. Product Listing
- 7.15.5. Entropy